Infusion Pumps & the Global Crisis: A Smarteeva Perspective

Baxter: SIGMA Spectrum and Spectrum IQ Recalls

FDA recalled Baxter’s SIGMA Spectrum Infusion Pumps with Master Drug Library and Spectrum IQ Infusion Systems with Dose IQ Safety Software. Baxter received more than 130 complaints and 3 serious injuries, leading to a Class I recall notice.

The core issue: false alarms. Unnecessary alarm stoppages delay patient treatment and contribute to clinician fatigue. FDA specifically cited the alarm-induced fatigue problem in its recall notice. When clinicians cannot distinguish real alarms from false ones, the safety system becomes a safety risk.

Becton Dickinson: Alaris Infusion Pump Recalls

Since 2020, BD’s Alaris infusion pumps have been the subject of more than six Class I hardware and software recalls. The issues span both the physical device and the software that controls it. After years of recalls, BD received FDA clearance to proceed with a remediation plan covering hardware and software upgrades.

The Alaris case is notable for the duration and frequency of recalls. Multiple Class I events for the same device family over a multi-year period is a signal that post-market surveillance systems need to track continuously, not review quarterly.

Smiths Medical: Manufacturing and Delivery Issues

Keywords: Smiths Medical infusion pump issues, infusion pump safety concerns

Smiths Medical warned of manufacturing issues causing false alarms and, in some cases, under-delivery or complete non-delivery of fluids. When an infusion pump fails to deliver medication, the clinical consequences range from treatment delay to patient harm.

The Common Thread: Software Complexity Outpacing Quality Assurance

All three manufacturers are producing smarter, more automated pumps. The automation itself is a quality risk when software updates, sensor calibration, and alarm logic are not validated at the same pace as product development. The devices that are supposed to reduce clinician workload are creating new categories of complaints.

For manufacturers in this category, the question is not whether recalls will happen. It is whether your surveillance system catches the signal before it becomes a Class I event.

How Smarteeva Monitors Recall Patterns at This Scale

Smarteeva’s platform manages 100,000+ recall notifications and 1 in 5 FDA recalls. The recall management module matches notices to actual inventory, deduplicates automatically, routes to the right person, and reconciles in real time.

MDREngine tracks 2.6M+ global safety records. Quality teams can set alerts for specific device categories, monitor competitor recall patterns, and cross-reference internal complaint trends against industry data. The infusion pump recall pattern described above is exactly the kind of signal MDREngine surfaces before it reaches your legal department.

100K+ recall notifications managed on Smarteeva

1 in 5 FDA recalls managed through the platform

2.6M+ global safety records in MDREngine

Closing

The infusion pump recall pattern is a case study in why reactive post-market surveillance fails. Three manufacturers. Multiple Class I events. Years of recurring issues. The data existed before every recall. The systems to act on it did not. Smarteeva was built to close that gap.

‍